Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide.

Chen L, Li JH, Kaur V, Muhammad A, Fernandez M, Hudson MS, Goldfine AB, Florez JC.

Diabet Med. 2019 Nov 10. doi: 10.1111/dme.14176. [Epub ahead of print]

PMID:
31709648
2.

Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.

Aday AW, Goldfine AB, Gregory JM, Beckman JA.

Obesity (Silver Spring). 2019 Nov;27(11):1812-1819. doi: 10.1002/oby.22602. Epub 2019 Oct 1.

PMID:
31571412
3.

Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.

Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A; PERL Study Group.

Diabetes Care. 2019 Aug;42(8):1454-1463. doi: 10.2337/dc19-0342. Epub 2019 Jun 11.

PMID:
31186299
4.

Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.

Mulla CM, Goldfine AB, Dreyfuss JM, Houten S, Pan H, Pober DM, Wewer Albrechtsen NJ, Svane MS, Schmidt JB, Holst JJ, Craig CM, McLaughlin TL, Patti ME.

Obes Surg. 2019 Jul;29(7):2092-2099. doi: 10.1007/s11695-019-03845-0.

PMID:
30976983
5.

PET-CT reveals increased intestinal glucose uptake after gastric surgery.

Franquet E, Watts G, Kolodny GM, Goldfine AB, Patti ME.

Surg Obes Relat Dis. 2019 Apr;15(4):643-649. doi: 10.1016/j.soard.2019.01.018. Epub 2019 Jan 25.

PMID:
30773442
6.

Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes.

Grizales AM, Patti ME, Lin AP, Beckman JA, Sahni VA, Cloutier E, Fowler KM, Dreyfuss JM, Pan H, Kozuka C, Lee A, Basu R, Pober DM, Gerszten RE, Goldfine AB.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):3038-3049. doi: 10.1210/jc.2018-00507.

7.

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.

Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC.

BMJ. 2018 Feb 6;360:k119. doi: 10.1136/bmj.k119.

8.
9.

Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia.

Laguna Sanz AJ, Mulla CM, Fowler KM, Cloutier E, Goldfine AB, Newswanger B, Cummins M, Deshpande S, Prestrelski SJ, Strange P, Zisser H, Doyle FJ 3rd, Dassau E, Patti ME.

Diabetes Technol Ther. 2018 Feb;20(2):127-139. doi: 10.1089/dia.2017.0298.

10.

The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia.

Fernandes GW, Bocco BMLC, Fonseca TL, McAninch EA, Jo S, Lartey LJ, O-Sullivan I, Unterman TG, Preite NZ, Voigt RM, Forsyth CB, Keshavarzian A, Sinkó R, Goldfine AB, Patti ME, Ribeiro MO, Gereben B, Bianco AC.

Cell Rep. 2018 Jan 9;22(2):523-534. doi: 10.1016/j.celrep.2017.12.053.

11.

Heterogeneity of proliferative markers in pancreatic β-cells of patients with severe hypoglycemia following Roux-en-Y gastric bypass.

Patti ME, Goldfine AB, Hu J, Hoem D, Molven A, Goldsmith J, Schwesinger WH, La Rosa S, Folli F, Kulkarni RN.

Acta Diabetol. 2017 Aug;54(8):737-747. doi: 10.1007/s00592-017-1001-2. Epub 2017 May 17.

12.

Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial.

Salastekar N, Desai T, Hauser T, Schaefer EJ, Fowler K, Joseph S, Shoelson SE, Goldfine AB; TINSAL-CVD study team.

Diabetes Obes Metab. 2017 Oct;19(10):1458-1462. doi: 10.1111/dom.12940. Epub 2017 Jul 6.

13.

Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Goldfine AB, Shoelson SE.

J Clin Invest. 2017 Jan 3;127(1):83-93. doi: 10.1172/JCI88884. Epub 2017 Jan 3. Review.

14.

Ebselen does not improve oxidative stress and vascular function in patients with diabetes: a randomized, crossover trial.

Beckman JA, Goldfine AB, Leopold JA, Creager MA.

Am J Physiol Heart Circ Physiol. 2016 Dec 1;311(6):H1431-H1436. doi: 10.1152/ajpheart.00504.2016. Epub 2016 Oct 7.

15.

Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism.

Lerin C, Goldfine AB, Boes T, Liu M, Kasif S, Dreyfuss JM, De Sousa-Coelho AL, Daher G, Manoli I, Sysol JR, Isganaitis E, Jessen N, Goodyear LJ, Beebe K, Gall W, Venditti CP, Patti ME.

Mol Metab. 2016 Aug 6;5(10):926-936. doi: 10.1016/j.molmet.2016.08.001. eCollection 2016 Oct.

16.

Physical Activity in Obese Type 2 Diabetes After Gastric Bypass or Medical Management.

Panosian J, Ding SA, Wewalka M, Simonson DC, Goebel-Fabbri A, Foster K, Halperin F, Vernon A, Goldfine AB.

Am J Med. 2017 Jan;130(1):83-92. doi: 10.1016/j.amjmed.2016.07.019. Epub 2016 Aug 20.

17.

Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins.

Hauser TH, Salastekar N, Schaefer EJ, Desai T, Goldfine HL, Fowler KM, Weber GM, Welty F, Clouse M, Shoelson SE, Goldfine AB; Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) Study Team.

JAMA Cardiol. 2016 Jul 1;1(4):413-23. doi: 10.1001/jamacardio.2016.0605.

PMID:
27438317
18.
19.

How common is hypoglycemia after gastric bypass?

Goldfine AB, Patti ME.

Obesity (Silver Spring). 2016 Jun;24(6):1210-1. doi: 10.1002/oby.21520. No abstract available.

20.

Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?

Smith RJ, Goldfine AB, Hiatt WR.

Diabetes Care. 2016 May;39(5):738-42. doi: 10.2337/dc15-2237.

PMID:
27208377
21.

IMPROVEMENTS IN METABOLIC CONTROL IN ADULTS WITH TYPE 2 DIABETES FOLLOWING REFERRAL TO A DIABETES CENTER, 2005-2010.

Mehta SN, Goldfine AB, Abrahamson MJ, McMullen W, Laffel LM.

Endocr Pract. 2016 Jun;22(6):689-98. doi: 10.4158/EP151080.OR. Epub 2016 Jan 27.

22.

Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.

Patorno E, Everett BM, Goldfine AB, Glynn RJ, Liu J, Gopalakrishnan C, Kim SC.

Diabetes Obes Metab. 2016 Aug;18(8):755-65. doi: 10.1111/dom.12665. Epub 2016 May 2.

PMID:
27003762
23.

Dietary Betaine Supplementation Increases Fgf21 Levels to Improve Glucose Homeostasis and Reduce Hepatic Lipid Accumulation in Mice.

Ejaz A, Martinez-Guino L, Goldfine AB, Ribas-Aulinas F, De Nigris V, Ribó S, Gonzalez-Franquesa A, Garcia-Roves PM, Li E, Dreyfuss JM, Gall W, Kim JK, Bottiglieri T, Villarroya F, Gerszten RE, Patti ME, Lerin C.

Diabetes. 2016 Apr;65(4):902-12. doi: 10.2337/db15-1094. Epub 2016 Feb 8.

24.

The rollercoaster of post-bariatric hypoglycaemia.

Patti ME, Goldfine AB.

Lancet Diabetes Endocrinol. 2016 Feb;4(2):94-6. doi: 10.1016/S2213-8587(15)00460-X. Epub 2015 Dec 15. No abstract available.

PMID:
26701701
25.

SerpinB1 Promotes Pancreatic β Cell Proliferation.

El Ouaamari A, Dirice E, Gedeon N, Hu J, Zhou JY, Shirakawa J, Hou L, Goodman J, Karampelias C, Qiang G, Boucher J, Martinez R, Gritsenko MA, De Jesus DF, Kahraman S, Bhatt S, Smith RD, Beer HD, Jungtrakoon P, Gong Y, Goldfine AB, Liew CW, Doria A, Andersson O, Qian WJ, Remold-O'Donnell E, Kulkarni RN.

Cell Metab. 2016 Jan 12;23(1):194-205. doi: 10.1016/j.cmet.2015.12.001. Epub 2015 Dec 15.

26.

Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes.

Yu EW, Wewalka M, Ding SA, Simonson DC, Foster K, Holst JJ, Vernon A, Goldfine AB, Halperin F.

J Clin Endocrinol Metab. 2016 Feb;101(2):714-22. doi: 10.1210/jc.2015-3437. Epub 2015 Nov 24.

27.

Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements.

McIver DJ, Grizales AM, Brownstein JS, Goldfine AB.

J Nutr. 2015 Dec;145(12):2675-82. doi: 10.3945/jn.115.214569. Epub 2015 Oct 7.

28.

New lessons from gastric bypass: Impact of glucose-independent islet function.

Goldfine AB, Patti ME.

Obesity (Silver Spring). 2015 Oct;23(10):1942-3. doi: 10.1002/oby.21259. Epub 2015 Sep 8. No abstract available.

29.

Diabetes primes neutrophils to undergo NETosis, which impairs wound healing.

Wong SL, Demers M, Martinod K, Gallant M, Wang Y, Goldfine AB, Kahn CR, Wagner DD.

Nat Med. 2015 Jul;21(7):815-9. doi: 10.1038/nm.3887. Epub 2015 Jun 15.

30.

Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Ding SA, Simonson DC, Wewalka M, Halperin F, Foster K, Goebel-Fabbri A, Hamdy O, Clancy K, Lautz D, Vernon A, Goldfine AB.

J Clin Endocrinol Metab. 2015 Jul;100(7):2546-56. doi: 10.1210/jc.2015-1443. Epub 2015 Apr 24.

31.

Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes.

Caramori ML, Kim Y, Goldfine AB, Moore JH, Rich SS, Mychaleckyj JC, Kirkpatrick D, Nickerson H, Krolewski AS, Mauer M.

J Clin Endocrinol Metab. 2015 Jun;100(6):E876-82. doi: 10.1210/jc.2014-4465. Epub 2015 Apr 14.

PMID:
25871838
32.

Insulin response to oral stimuli and glucose effectiveness increased in neuroglycopenia following gastric bypass.

Patti ME, Li P, Goldfine AB.

Obesity (Silver Spring). 2015 Apr;23(4):798-807. doi: 10.1002/oby.21043. Epub 2015 Mar 7.

33.

Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus.

Rubin MR, Goldfine AB, McMahon DJ, Donovan DS, Cremers S, Dworakowski E, Schaefer EJ, Shoelson SE, Silverberg SJ.

Endocrine. 2015 Nov;50(2):504-7. doi: 10.1007/s12020-015-0535-8. Epub 2015 Feb 1. No abstract available.

34.

Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.

Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA.

J Diabetes Complications. 2015 Apr;29(3):433-7. doi: 10.1016/j.jdiacomp.2015.01.004. Epub 2015 Jan 13.

35.

Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.

Milian J, Goldfine AB, Zuflacht JP, Parmer C, Beckman JA.

Acta Diabetol. 2015 Aug;52(4):709-15. doi: 10.1007/s00592-014-0708-6. Epub 2015 Jan 8.

36.

Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study.

Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, Jerosch-Herold M, Lima JA, Ding J, Allison MA.

JACC Cardiovasc Imaging. 2014 Dec;7(12):1221-35. doi: 10.1016/j.jcmg.2014.07.017. Epub 2014 Nov 5.

37.

Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.

Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB.

Acta Diabetol. 2014 Dec;51(6):1015-23. doi: 10.1007/s00592-014-0663-2. Epub 2014 Oct 14.

38.

Glycemia and cognitive function in metabolic syndrome and coronary heart disease.

Avadhani R, Fowler K, Barbato C, Thomas S, Wong W, Paul C, Aksakal M, Hauser TH, Weinger K, Goldfine AB.

Am J Med. 2015 Jan;128(1):46-55. doi: 10.1016/j.amjmed.2014.08.025. Epub 2014 Sep 16.

39.

Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus.

Goldfine AB, Phua EJ, Abrahamson MJ.

Circulation. 2014 Jun 17;129(24):2567-73. doi: 10.1161/CIRCULATIONAHA.113.006634. Review. No abstract available.

40.

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.

Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH.

Ann Rheum Dis. 2015 Nov;74(11):1968-75. doi: 10.1136/annrheumdis-2014-205216. Epub 2014 Jun 11.

41.

Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial.

Halperin F, Ding SA, Simonson DC, Panosian J, Goebel-Fabbri A, Wewalka M, Hamdy O, Abrahamson M, Clancy K, Foster K, Lautz D, Vernon A, Goldfine AB.

JAMA Surg. 2014 Jul;149(7):716-26. doi: 10.1001/jamasurg.2014.514.

42.

Insulin regulates carboxypeptidase E by modulating translation initiation scaffolding protein eIF4G1 in pancreatic β cells.

Liew CW, Assmann A, Templin AT, Raum JC, Lipson KL, Rajan S, Qiang G, Hu J, Kawamori D, Lindberg I, Philipson LH, Sonenberg N, Goldfine AB, Stoffers DA, Mirmira RG, Urano F, Kulkarni RN.

Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2319-28. doi: 10.1073/pnas.1323066111. Epub 2014 May 19.

43.

Impaired fasting glucose and body mass index as determinants of mortality in ALLHAT: is the obesity paradox real?

Shah RV, Abbasi SA, Yamal JM, Davis BR, Barzilay J, Einhorn PT, Goldfine AB; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2014 Jun;16(6):451-8. doi: 10.1111/jch.12325. Epub 2014 Apr 29. Erratum in: J Clin Hypertens (Greenwich). 2014 Oct;16(10):770-1. Goldfine, Allison [corrected to Goldfine, Alison B].

44.

Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.

Goldfine AB, Jablonski KA, Shoelson SE, Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team.

Diabetes Care. 2014 May;37(5):e112. doi: 10.2337/dc14-0222. No abstract available.

45.

Diabetes improvement following Roux-en-Y gastric bypass: understanding dynamic changes in insulin secretion and action.

Goldfine AB, Patti ME.

Diabetes. 2014 May;63(5):1454-6. doi: 10.2337/db13-1918. No abstract available.

46.

Hypoglycemia after gastric bypass: the dark side of GLP-1.

Patti ME, Goldfine AB.

Gastroenterology. 2014 Mar;146(3):605-8. doi: 10.1053/j.gastro.2014.01.038. Epub 2014 Jan 24. No abstract available.

47.

Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin.

Wewalka M, Patti ME, Barbato C, Houten SM, Goldfine AB.

J Clin Endocrinol Metab. 2014 Apr;99(4):1442-51. doi: 10.1210/jc.2013-3367. Epub 2014 Jan 16.

48.

Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use.

Phua EJ, Lopez X, Ramus J, Goldfine AB.

Diabetes Care. 2013 Dec;36(12):e204-5. doi: 10.2337/dc13-1123. No abstract available.

49.

The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.

Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, Monnier VM; TINSAL-T2D Research Consortium.

Diabetes Care. 2014 Apr;37(4):1083-91. doi: 10.2337/dc13-1527. Epub 2013 Nov 19.

50.

Where are the health care cost savings with bariatric surgery in obesity management?

Goldfine AB, Vernon A, Zinner M.

JAMA Surg. 2014 Jan;149(1):5-6. doi: 10.1001/jamasurg.2013.3060. No abstract available.

PMID:
24195967

Supplemental Content

Loading ...
Support Center